NASDAQ:CLLS - Nasdaq - US15117K1034 - ADR - Currency: USD
Taking everything into account, CLLS scores 3 out of 10 in our fundamental rating. CLLS was compared to 556 industry peers in the Biotechnology industry. CLLS may be in some trouble as it scores bad on both profitability and health. CLLS is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -14.12% | ||
ROE | -41.34% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 4.64% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | 4.88 | ||
Altman-Z | -0.87 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.73 | ||
Quick Ratio | 1.73 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 10.48 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2
-0.33 (-14.16%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2.72 | ||
P/FCF | 10.48 | ||
P/OCF | 8.73 | ||
P/B | 1.53 | ||
P/tB | 1.54 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -14.12% | ||
ROE | -41.34% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 4.64% | ||
FCFM | 25.96% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | 4.88 | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 19.36% | ||
Cap/Sales | 5.21% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.73 | ||
Quick Ratio | 1.73 | ||
Altman-Z | -0.87 |